


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **DAWNRAYS PHARMACEUTICAL (HOLDINGS) LIMITED**

## **東瑞製藥(控股)有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2348)**

### **POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 28 MAY 2021**

At the annual general meeting of Dawnrays Pharmaceutical (Holdings) Ltd. (the “Company”) held on 28 May 2021 (the “Annual General Meeting”), a poll was demanded by the Chairman of the meeting for voting on all resolutions as set out in the notice of the Annual General Meeting dated 20 April 2021.

As at the date of the Annual General Meeting, a total of 1,496,261,000 shares of the Company were in issue, which was the total number of shares entitling the shareholders of the Company (the “Shareholders”) to attend and vote for or against all resolutions. There were no restrictions on Shareholders to cast votes on any of the proposed resolutions at the Annual General Meeting.

Tricor Abacus Limited, the Company’s branch share registrar and transfer office in Hong Kong, was appointed as scrutineer for the voting process at the Annual General Meeting. All the resolutions were approved by Shareholders and poll results were as follows:

Ordinary Resolutions		Number of Votes (%) <sup>#</sup>	
		For	Against
1.	To receive and consider the audited consolidated financial statements and the reports of the directors and auditors for the year ended 31 December 2020.	1,071,155,765 (99.97%)	268,000 (0.03%)
2.	To declare a final dividend of HK\$0.05 per share for the year ended 31 December 2020.	1,071,423,765 (100.00%)	0 (0.00%)
3.	To declare a special dividend of HK\$0.05 per share for the year ended 31 December 2020.	1,071,423,765 (100.00%)	0 (0.00%)
4.	(I) To re-elect Mr. Chen Shaojun as an executive director of the Company.	959,694,126 (89.57%)	111,729,639 (10.43%)
	(II) To re-elect Mr. Ede, Ronald Hao Xi as an independent non-executive director of the Company.	893,704,100 (83.41%)	177,719,665 (16.59%)
	(III) To re-elect Ms. Lam Ming Yee Joan as an independent non-executive director of the Company.	942,479,100 (87.97%)	128,944,665 (12.03%)
	(IV) To authorize the board of directors of the Company to fix the remuneration of the directors.	966,161,313 (90.18%)	105,262,452 (9.82%)

Ordinary Resolutions		Number of Votes (%) <sup>#</sup>	
		For	Against
5.	To re-appoint Ernst & Young as Auditors of the Company and authorize the board of directors to fix their remuneration.	1,071,423,765 (100.00%)	0 (0.00%)
6.	Ordinary resolution no. 6 set out in the notice of the Annual General Meeting (to grant a general mandate to the directors of the Company to allot, issue and deal with new shares in the Company not exceeding 20% of the issued share capital of the Company).	887,403,942 (82.82%)	184,019,823 (17.18%)
7.	Ordinary resolution no. 7 set out in the notice of the Annual General Meeting (to grant a general mandate to the directors of the Company to repurchase shares in the Company not exceeding 10% of the issued share capital of the Company).	1,071,423,765 (100.00%)	0 (0.00%)
8.	Ordinary resolution no. 8 set out in the notice of the Annual General Meeting (to extend the general mandate to the directors of the Company to allot, issue and deal with new shares in the Company by an amount not exceeding the amount of shares in the Company repurchased by the Company).	936,178,942 (87.38%)	135,244,823 (12.62%)

<sup>#</sup>All percentages are rounded to two decimal places.

As more than 50% of the votes were cast in favour of each of the resolutions, all the resolutions proposed at the Annual General Meeting were duly passed as ordinary resolutions of the Company.

By Order of the Board  
Dawnrays Pharmaceutical (Holdings) Ltd.  
Pang Kit Ling  
Company Secretary

Hong Kong, 28 May 2021

*As at the date of this announcement, the Board of the Company comprises three executive directors, namely Ms. Li Kei Ling, Mr. Hung Yung Lai and Mr. Chen Shaojun; one non-executive director, namely Mr. Leung Hong Man; three independent non-executive directors, namely Mr. Lo Tung Sing Tony, Mr. Ede, Ronald Hao Xi and Ms. Lam Ming Yee Joan.*

*\* for identification purpose only*